PRESS RELEASE published on 12/23/2025 at 14:02, 10 months 27 days ago FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco® – Strengthening US Presence with Zydus as Commercialization Partner FDA approves Formycon's Nufymco® as interchangeable Ranibizumab Biosimilar, partnering with Zydus for commercialization in the US, expanding access to retinal therapies FDA Approval Formycon Zydus Interchangeable Biosimilar Nufymco®
BRIEF published on 12/09/2025 at 13:09, 11 months 10 days ago Accord de licence entre Formycon et Zydus Forge pour le FYB206 en Amérique du Nord Formycon Biosimilaire Contrat De Licence Keytruda Zydus
BRIEF published on 12/09/2025 at 13:09, 11 months 10 days ago Formycon and Zydus Forge Licensing Agreement for FYB206 in North America Licensing Agreement Biosimilar Formycon Keytruda Zydus
PRESS RELEASE published on 12/09/2025 at 13:04, 11 months 10 days ago Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada Formycon AG and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada. Agreement includes milestone payments, development progress, and upcoming data release Formycon AG Biosimilar Keytruda Zydus Exclusive Licensing
BRIEF published on 12/04/2025 at 06:35, 11 months 16 days ago Formycon et MS Pharma collaborent pour le biosimilaire de Keytruda® au Moyen-Orient et en Afrique du Nord MS Pharma Keytruda® FYB206 Accord Sur Les Biosimilaires Marché MENA Partenariat Formycon
BRIEF published on 12/04/2025 at 06:35, 11 months 16 days ago Formycon and MS Pharma Collaborate for Keytruda® Biosimilar in MENA MS Pharma Biosimilar Agreement Keytruda® FYB206 MENA Market Formycon Partnership
PRESS RELEASE published on 12/04/2025 at 06:30, 11 months 16 days ago Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region Formycon AG and MS Pharma enter exclusive partnership to commercialize Keytruda biosimilar FYB206 in MENA region, aiming to enhance cancer drug access MENA Region MS Pharma Biosimilar Formycon Keytruda
BRIEF published on 11/24/2025 at 06:35, 11 months 26 days ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
BRIEF published on 11/24/2025 at 06:35, 11 months 26 days ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE published on 11/24/2025 at 06:30, 11 months 26 days ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
Published on 11/20/2026 at 02:00, 9 hours 17 minutes ago PPX Mining Announces Completion of Debt Settlement
Published on 11/19/2026 at 23:30, 11 hours 47 minutes ago EQ Inc. Reports Third Quarter 2026 Financial Results
Published on 11/19/2026 at 23:00, 12 hours 17 minutes ago Redwood AI Reports Positive Interim Q-SAFE Findings Supporting Quantum-Assisted Chemical Safety Screening
Published on 11/19/2026 at 22:35, 12 hours 42 minutes ago Pampa Medina Drilling Intersects 102m of 1.0% Cu and 5.1g/t Ag from SPRD-21; 22m of 2.1% Cu and 10g/t Ag from SPRD-18; and 8m of 3.21% Cu and 27.5g/t Ag from SPRD-24
Published on 11/19/2026 at 22:25, 12 hours 52 minutes ago Kidoz Reports Record Nine-Month Revenue of US$9,900,750
Published on 11/20/2026 at 11:05, 11 minutes ago BIRKENSTOCK EXPANDS IN THE GREEK MARKET WITH THE OPENING OF TWO NEW RETAIL DESTINATIONS IN ATHENS
Published on 11/20/2026 at 10:59, 18 minutes ago EQS-Adhoc: Revenue decreases by approximately 28.6% in the first half of the financial year // Positive revenue and earnings outlook for the 2026/2027 financial year remains unchanged
Published on 11/20/2026 at 10:34, 42 minutes ago Finexity AG: mwb analytics initiates coverage of Finexity AG with Buy rating and EUR 14.00 price target
Published on 11/20/2026 at 10:13, 1 hour 3 minutes ago JIMMY encourages a closer look at water purifiers beyond the price tag
Published on 11/20/2026 at 10:04, 1 hour 12 minutes ago Original-Research: Energiekontor AG (von First Berlin Equity Research GmbH): Buy
Published on 11/19/2026 at 19:00, 16 hours 17 minutes ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 19:00, 16 hours 17 minutes ago MR.BRICOLAGE : PERSPECTIVES POUR L'EXERCICE 2026
Published on 11/19/2026 at 08:30, 1 day 2 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing
Published on 11/19/2026 at 08:30, 1 day 2 hours ago Souveraineté des données : Cegedim ouvre EB6, un datacenter nouvelle génération pour l'IA et la haute densité